Covid-19 Vaccines Returned Trillions, Study Finds
Modelled estimates range from $6.43 trillion to $64.3 trillion depending on the valuation method used.
Updated on Nov. 5, 2026 in COVID-19
Live Poll
Do you think government spending on public health protects the economy too?
Researchers reanalyzed the economic return of covid-19 vaccines, estimating $6.43 trillion to $64.3 trillion in global value gained in the first 12 months after rollout, against $79.4 billion invested in development. The estimate revises an earlier preprint figure of $4.8 trillion to $37.9 trillion made during peer review.
Why it matters
The revised range shows how strongly the method chosen shapes the headline number: a quality-of-life cost-effectiveness approach and a public-sector cost-benefit approach produce very different totals. For readers, the work reinforces that vaccination protects health and economies alike, while the wide range signals the estimates are model-based rather than precise measurements.
This is a modelling study, not a trial, drawing on data from 173 countries on averted hospitalisations, productivity losses and lives saved. Its estimates of 14 million to 20 million deaths prevented in the first year are model outputs, and the economic returns depend heavily on which valuation method is applied.
The details
The analysis applied two economic frameworks: a cost-effectiveness approach that factors in quality of life, which produced the lower figure, and a cost-benefit approach used in public-sector decision-making, which produced the higher one. Both drew on modelled counts of hospitalisations averted, lost productivity avoided and lives saved. During peer review, the researchers changed from the Value of Statistical Life Years to the Value of Statistical Life on reviewers' advice, a shift that substantially raised the cost-benefit estimate.
Timeline
First 12 months after vaccine rollout: the period over which benefits were measured across 173 countries.
The next 10 years: the window in which the researchers describe the probability of another pandemic as significant.
Health Landscape
Economic valuations of vaccination have become a standard way to justify public health spending, and this revision shows how sensitive those totals are to methodology. The gap between the two valuation approaches highlights an ongoing debate over how to put a monetary value on avoided deaths and quality of life in population-level health policy.
The findings reinforce that covid-19 vaccination has been associated with large population-level health and economic benefits, particularly in higher-income settings where access came sooner. Readers who want to understand their own vaccination status or booster considerations should discuss them with a physician.
The takeaway
Vaccine benefit estimates are highly sensitive to the valuation method used, so the headline figures should be read as modelled ranges rather than fixed totals. Public health planners and readers alike should note that the researchers also flag a significant probability of another pandemic within the next decade.
Further reading
For broader background on the pandemic's health and economic toll, explore the COVID-19 section.
Source note: This article includes information reported by New Scientist.
Live Poll
Do you think government spending on public health protects the economy too?
